Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921435" target="_blank" >RIV/00023752:_____/25:43921435 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/25:43927874
Result on the web
<a href="https://www.cambridge.org/core/journals/european-psychiatry/article/use-of-psychedelic-treatments-in-psychiatric-clinical-practice-an-epa-policy-paper/340B7D729CF69904BB989B24FA0D60F7" target="_blank" >https://www.cambridge.org/core/journals/european-psychiatry/article/use-of-psychedelic-treatments-in-psychiatric-clinical-practice-an-epa-policy-paper/340B7D729CF69904BB989B24FA0D60F7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1192/j.eurpsy.2024.1806" target="_blank" >10.1192/j.eurpsy.2024.1806</a>
Alternative languages
Result language
angličtina
Original language name
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
Original language description
Background Recent years show an exponential increased interest ("renaissance") in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape. The European Psychiatric Association (EPA) acknowledges both the therapeutic potential of psychedelic substances and the challenges for both research and clinical implementation. Steps need to be taken toward a well-balanced policy based upon sound scientific evidence and research, aiming at safe, ethical responsible integration of psychedelic therapy available for all patients who can potentially benefit.Methods In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments.Results In addition to an overview of the current evidence and hypotheses of working mechanisms of psychedelic treatment, this policy paper specifically highlights the importance of the psychosocial components of the treatment as well as the ethical and professional aspects playing a role in real-world implementation.Conclusions Four recommendations are formulated for further research and clinical implementation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Psychiatry
ISSN
0924-9338
e-ISSN
1778-3585
Volume of the periodical
68
Issue of the periodical within the volume
1
Country of publishing house
FR - FRANCE
Number of pages
7
Pages from-to
"e3"
UT code for WoS article
001393055300001
EID of the result in the Scopus database
2-s2.0-85214906699